Every Form 4 that SAB Biotherapeutics, Inc. Warrant (SABSW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SABSW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SABSW filings page.
SAB Biotherapeutics, Inc. (SABS) reported that Chief Medical Officer Alexandra Kropotova had 473 shares of common stock withheld on September 17, 2026 to satisfy tax withholding requirements upon vesting of restricted stock units. After this tax-withholding disposition, she holds 41,853 shares directly, including vested and unvested RSU-related shares.
SAB Biotherapeutics, Inc. chief medical officer Alexandra Kropotova reported a Form 4 showing a tax-withholding disposition of 988 shares of common stock. These shares were withheld to cover taxes on the vesting of restricted stock units. After this event, she holds 42,308 shares, including 5,150 unvested RSUs.
SAB Biotherapeutics, Inc. chief medical officer Alexandra Kropotova reported a routine tax-related share withholding. On the vesting of restricted stock units, 988 shares of common stock were withheld to satisfy tax obligations, rather than sold in the market. After this disposition, she holds 43,296 shares directly, including 8,743 unvested RSUs, each representing a right to receive one share of common stock.